- Home
- NUVB
NUVB
Nuvation Bio Inc.
as 09-17-2025 4:00pm EST
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $8.17 | AVG Volume (30 days): | 6.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.54 - $4.09 | Next Earning Date: | 11-05-2025 |
| Revenue: | $14,355,000 | Revenue Growth: | 900.35% |
| Revenue Growth (this year): | 332.8% | Revenue Growth (next year): | 360.12% |
Latest Nuvation Bio Inc. News
NUVB Breaking Stock News: Dive into NUVB Ticker-Specific Updates for Smart Investing
Argus Research
6 days ago
Daily – Vickers Top Insider Picks for 09/12/2025
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 06/25/2025
Insider Monkey
3 months ago
RBC Capital Lowers PT on Nuvation Bio (NUVB) to $6 But Keeps a Buy Rating
MT Newswires
3 months ago
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of Powell Testimony
MT Newswires
3 months ago
Nuvation Bio Says Taletrectinib Added as Preferred Agent in National Comprehensive Cancer Network for Lung Cancer
Business Wire
3 months ago
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers
Barchart
3 months ago
Are These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?
Simply Wall St.
3 months ago
Founder of Nuvation Bio David Hung Buys More Stock
Compare NUVB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NUVB Nuvation Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.